PT  - JOURNAL ARTICLE
AU  - Santos, Dheiver
TI  - Breast Cancer Survival Prediction using Machine Learning and Gene Expression Profiles
AID  - 10.1101/2022.01.22.22269470
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.22.22269470
4099  - http://medrxiv.org/content/early/2022/01/25/2022.01.22.22269470.short
4100  - http://medrxiv.org/content/early/2022/01/25/2022.01.22.22269470.full
AB  - Breast cancer is one of the most common cancers with a high mortality rate among women. It is also the most frequent cause of cancer death in this population, with an estimated 684,996 deaths for that year (15.5% of cancer deaths in women) (IARC, 2020). In Brazil, breast cancer is also the most common type of cancer in women from all regions, after non-melanoma skin cancer. Therefore, an accurate and reliable system is needed for the early diagnosis of this cancer. Machine learning explores the study and construction of algorithms that can learn from their mistakes and make predictions about data. The results here are excellent with an accuracy and precision level of around 79%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Institution BRIDGE gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at cBioPortal